نتایج جستجو برای: free treatment overall

تعداد نتایج: 2196605  

Journal: :Molecular and clinical oncology 2016
Chengwei Peng Jialing Wang Jarred P Tanksley Bret C Mobley Gregory D Ayers Paul L Moots Stephen W Clark

Prolonged treatment with adjuvant valganciclovir has been shown in one retrospective study to exert a significant effect on overall survival (OS) in newly diagnosed patients with glioblastoma multiforme (GBM). However, studies evaluating the effectiveness of valganciclovir in the treatment of recurrent GBM have not been performed. We evaluated the effect of valganciclovir in the recurrent setti...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2010
Rajul K Jain J Jack Lee David Hong Maurie Markman Jing Gong Aung Naing Jennifer Wheler Razelle Kurzrock

PURPOSE To safely assess new drugs, cancer patients in initial cohorts of phase I oncology studies receive low drug doses. Doses are successively increased until the maximum tolerated dose (MTD) is determined. Because traditional chemotherapy is often more effective near the MTD, ethical concerns have been raised about administration of low drug doses to phase I patients. However, a substantial...

2012
Cesare Gridelli Paolo Maione Antonio Rossi Clorinda Schettino Maria Anna Bareschino Paola Claudia Sacco Giovanni Palazzolo Francesca Casaluce Assunta Sgambato Fortunato Ciardiello

„ Switch maintenance treatment has been found to be an effective strategy in prolonging overall survival. The benefit in progression-free survival and overall survival, reported with pemetrexed in patients with nonsquamous histology and erlotinib in unselected patients as switch maintenance, and their favorable toxicity profile allow them to be used as maintenance treatment after induction ther...

2015
Yasuyoshi Sato Satoshi Matsusaka Mitsukuni Suenaga Eiji Shinozaki Nobuyuki Mizunuma

BACKGROUND Cetuximab and bevacizumab reportedly improve the survival of patients with metastatic colorectal cancer (mCRC), but their most effective sequence of administration is unknown. The aim of this study was to compare the survival of patients with mCRC treated with cetuximab after bevacizumab failure with that of patients with mCRC without previous bevacizumab therapy. PATIENTS AND METH...

*, Noorieh Sharifi Sistani Fatemeh Homaee Malihe Hasanzadeh Sima Kadkhodayan Zohreh Yousefi

Uterine sarcoma is a rare tumor of mesodermal origin, accounting for 2-6% of uterine malignancies. Leiomyosarcoma (LMS) has been reported in only 1% of all uterine malignancies and is regarded as the most common primary uterine sarcoma. Herein, we present a case of LMS with unusual macroscopic features. The patient was a 61-year-old woman with LMS, which consisted of a large cystic mass (88×136...

Journal: :Haematologica 2015
Meletios A Dimopoulos Katja C Weisel Kevin W Song Michel Delforge Lionel Karlin Hartmut Goldschmidt Philippe Moreau Anne Banos Albert Oriol Laurent Garderet Michele Cavo Valentina Ivanova Adrian Alegre Joaquin Martinez-Lopez Christine Chen Andrew Spencer Stefan Knop Nizar J Bahlis Christoph Renner Xin Yu Kevin Hong Lars Sternas Christian Jacques Mohamed H Zaki Jesus F San Miguel

Patients with refractory or relapsed and refractory multiple myeloma who no longer receive benefit from novel agents have limited treatment options and short expected survival. del(17p) and t(4;14) are correlated with shortened survival. The phase 3 MM-003 trial demonstrated significant progression-free and overall survival benefits from treatment with pomalidomide plus low-dose dexamethasone c...

2013
Janette Greenhalgh Adrian Bagust Angela Boland Michaela Blundell James Oyee Sophie Beale Yenal Dundar Juliet Hockenhull Chris Proudlove Patrick Chu

The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of rituximab (RTX) [Roche] to submit evidence for the clinical and cost effectiveness of RTX as first-line maintenance treatment for patients with follicular non-Hodgkin's lymphoma (fNHL) whose disease has responded to induction therapy with RTX plus cytotoxic chemotherapy (R-CTX) in accordance with the In...

Journal: :Lung Cancer 2010
Saeed Rafii Michael H Cullen

Until recently, the weight of evidence has supported the discontinuation of chemotherapy in advanced non-small-cell lung cancer (NSCLC) after 4-6 cycles of induction therapy. This allows patients with limited life expectancy a "treatment holiday." A minority of cases then go on to receive second-line therapy, although many deteriorate rapidly and never receive further active treatment. There ha...

Journal: :Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2015
Albina N Minlikeeva Jo L Freudenheim Wei-Hsuan Lo-Ciganic Kevin H Eng Grace Friel Brenda Diergaarde Francesmary Modugno Rikki Cannioto Emily Gower J Brian Szender Kassondra Grzankowski Kunle Odunsi Roberta B Ness Kirsten B Moysich

BACKGROUND Use of analgesics has been associated with lower risk of ovarian cancer, but, to date, very few studies have explored the association between analgesics and ovarian cancer survival. METHODS We examined the relationship between self-reported prediagnostic use of aspirin, ibuprofen, and acetaminophen and overall survival (OS), progression-free survival (PFS), ascites at the time of p...

2015
Yanhong Deng Yue Cai Jiayu Lin Ling Jiang Huabin Hu

OBJECTIVE To investigate the overall survival of patients with KRAS wild-type metastatic colorectal cancer (mCRC) after sequentially receiving both bevacizumab and cetuximab during the course of treatment. METHODS Twenty-six mCRC patients who received both bevacizumab and cetuximab at the Sun Yat-sen University Gastrointestinal Hospital were retrospectively analyzed. Group A (n = 8) comprised...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید